Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost–benefit analysis

被引：0
作者：
Savannah Gelhard
Amiee Maxwell
Howard Colman
Adam L. Cohen
Joe S. Mendez
机构：
[1] University of Utah,School of Medicine
[2] Huntsman Cancer Institute,Total Cancer Care Department
[3] Winona State University,Department of Neurosurgery, Huntsman Cancer Institute
[4] University of Utah,Division of Oncology, Huntsman Cancer Institute
[5] University of Utah,undefined
[6] Inova Schar Cancer Institute,undefined
来源：
Journal of Neuro-Oncology | 2022年 / 159卷
关键词：
Primary central nervous system lymphoma; Cost-benefit analysis; Consolidation; Value-driven outcome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：293 / 300
页数：7
相关论文
共 61 条
  • [1] Mendez JS(2018)The elderly left behind-changes in survival trends of primary central nervous system Lymphoma over the past 4 decades Neuro Oncol 20 687-694
  • [2] Ostrom QT(2017)Primary CNS Lymphoma J Clin Oncol 35 2410-2418
  • [3] Gittleman H(2013)How I treat CNS Lymphomas Blood 122 2318-2330
  • [4] Grommes C(2014)Primary CNS Lymphoma rituximab primary CNS Lymphoma J Clin Oncol 35 2013-2014
  • [5] DeAngelis LM(2000)Treatment for primary CNS Lymphoma: the next step J Clin Oncol 18 3144-3150
  • [6] Rubenstein JL(2005)Delayed neurotoxicity in primary central nervous system Lymphoma Arch Neurol 125 1403-1410
  • [7] Gupta NK(2015)R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS Lymphoma Blood 31 3061-3068
  • [8] Mannis GN(2013)Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS Lymphoma: CALGB 50202 (Alliance 50202) J Clin Oncol 39 7506-7506
  • [9] Templates N(2021)Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system Lymphoma: results of CALGB 51101 (Alliance) J Clin Oncol 16 282-e523
  • [10] Abrey LE(2016)High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS Lymphoma—a randomized phase III trial (MATRix) BMC Cancer 4 e510-833
1234567